Alex Dean

Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment)

Discussion created by Alex Dean on Feb 24, 2018

Fidaxomicin is an antibiotic that belongs to the class of the macrocyclics and is indicated for the treatment of CDI. In clinical trials, fidaxomicin, when compared to vancomycin, was non-inferior for the clinical cure of patients with CDI and superior for the reduction of recurrence rates, with a greater sustained response after 30 days. Of the patients included in the clinical trials, additional subgroup analyses were performed in patient subgroups with a higher risk of recurrence than the overall CDI population.